Kingstone Announces 2021 First Quarter Financial Results and Full Year 2021 Guidance
ACCESSWIRE
14 May 2021, 06:19 GMT+10
KINGSTON, NY / ACCESSWIRE / May 13, 2021 / Kingstone Companies, Inc. (NASDAQ:KINS) (the Company or Kingstone ), a Northeast regional property and casualty insurance holding company, today announced its financial results for the quarter ended March 31, 2021 and certain full year 2021 guidance. The Company will host a conference call for analysts and investors on May 14, 2021 at 8:30 a.m. Eastern Time, as previously announced on April 27, 2021.
2021 First Quarter Financial and Operational Highlights
(All results are compared to prior year period unless otherwise noted)
Loss per share of ($0.03) compared to ($0.50); Operating loss per share
Jim was most recently a systems development manager and has been with Kadant Johnson since 2006. Before Kadant Johnson he held various technical and commercial roles at Valmet-Enerdry and Voith. He succeeds John Lefkowitz who retired after 16 years at Kadant Johnson.
GEE Group Announces Full Exercise and Closing of Over-Allotment Option in Connection with its Underwritten Public Offering
ACCESSWIRE
29 Apr 2021, 06:31 GMT+10
JACKSONVILLE, FL / ACCESSWIRE / April 28, 2021 / GEE Group Inc. (NYSE American:JOB) ( GEE or the Company ), a provider of professional staffing services and solutions, today announced that the underwriter of its recent public offering exercised in full its 15% over-allotment option to purchase an additional 12,499,999 common shares (the option shares ) of the Company at the public offering price of $0.60 per share. GEE has closed the transaction and received gross proceeds from the sale of the option shares of approximately $7.5 million, before deducting the underwriting discount and commissions and offering expenses. The Company previously closed, on April 18, 2021, an underwritten public offering of 83,333,333 shares of its common stock at the public offering price of $0.60 per share (the firm shares ), for gross proc
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Vertex and CRISPR Therapeutics Announce Priority Medicines (PRIME) Designation Granted by the .
CRISPR Therapeutics AGApril 26, 2021 GMT
BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, an investigational, autologous,
ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT). CTX001 was previously granted PRIME designation for the treatment of sickle cell disease (SCD) in 2020.